Cerenome books $0.7M from CNSide diagnostic as cash stands at $4.9M
The company that previously traded as Plus Therapeutics reported its first diagnostic sales in the third quarter, with payer contracts widening and two clinical milestones due in 2027.
Cerenome, Inc. has started to turn its CNSide diagnostic into a revenue line. In third-quarter 2026 results published on 13 November, the company reported $0.7M of net revenue from the product, the first time it has booked sales from it. The company previously operated as Plus Therapeutics.
The commercial groundwork is being laid with private insurers first. Cerenome said it added payer agreements during the period, among them one with Aetna, and that its contracted coverage now spans roughly 190M lives. It expects Medicare reimbursement for CNSide in the first half of 2027. The summary does not give pricing, test volumes or the terms of the contracts, so the pace of uptake behind the $0.7M cannot be judged.
The balance sheet is the counterweight. Cerenome recorded a net loss of $8.7M for the quarter and ended it with $4.9M in cash, a balance smaller than a single quarter's loss. The facts available do not address financing plans or how long the cash will last.
On the drug side, interim Phase 1 ReSPECT-LM data for REYOBIQ in leptomeningeal metastases showed that none of the first 10 patients had a dose-limiting toxicity. Dosing and efficacy results were not provided, and the cohort is small. Separately, the Phase 2 trial of REYOBIQ in recurrent glioblastoma has finished enrolling patients, with topline results expected in mid-2027.
Why it matters
- CNSide shows a diagnostic building commercial payer contracts, including Aetna and about 190M contracted lives, before the Medicare decision expected in H1 2027.
- Cash of $4.9M against an $8.7M quarterly loss is the key counterparty consideration for any prospective partner or supplier.
- The REYOBIQ safety signal comes from an early cohort of 10 patients and does not amount to a full safety profile; no efficacy data were reported.
- Two dated catalysts to track: Medicare reimbursement in H1 2027 and Phase 2 glioblastoma topline data in mid-2027.
Company's press release (SEC filing): Cerenome, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
FDA lifts ARD-101 clinical hold in Prader-Willi; Aardvark to run open-label trial
